

E – Newsletter



Tuesday, September 13, 2022



In the today's Newsletter

- SYNkinase: **Newly updated products**

SYNkinase:

New Products Highlights in September 2022:

- Potent, highly selective and orally active SYK inhibitor, Lanraplenib (GS-9876) (SYN-1298)

Lanraplenib (GS-9876) is a highly selective and orally active SYK inhibitor (IC₅₀=9.5 nM) in development for the treatment of inflammatory diseases.

- Potent and highly selective PI3K δ (PI3K delta) inhibitor Parsaclisib (INCB050465) (SYN-1299)

Parsaclisib (INCB050465) is a potent and highly selective PI3K δ inhibitor with an IC₅₀ of 1 nM at 1 mM ATP in biochemical assay and approximately 20,000-fold selectivity for PI3K α , PI3K β , PI3K γ and 57 other kinases.

Contact Information:

Email: service@synmedchem.cn

SYNkinase

c/- Synthesis Med Chem USA Inc

PO Box 7890

San Diego, CA 92167

USA